|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200063151 |
|
最近更新日期: Date of Last Refreshed on: |
2022-08-31 22:42:25 |
|
注册时间: Date of Registration: |
2022-08-31 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于真实世界中医药干预新型冠状病毒轻型、无症状型患者的回顾性研究 |
|
Public title: |
The retrospective study on the intervention of traditional Chinese medicine in mild and asymptomatic infectors with COVID-19 in real world. |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于真实世界中医药干预新型冠状病毒轻型、无症状型患者的回顾性研究 |
|
Scientific title: |
The retrospective study on the intervention of traditional Chinese medicine in mild and asymptomatic infectors with COVID-19 in real world. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张顺先 |
研究负责人: |
田雨 |
|
Applicant: |
Zhang shunxian |
Study leader: |
Tian yu |
|
申请注册联系人电话: Applicant telephone: |
15221367406 |
研究负责人电话:
Study leader's |
13795491542 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhangshunxian110@163.com |
研究负责人电子邮件: Study leader's E-mail: |
tyrain2000@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区宛平南路725号 |
研究负责人通讯地址: |
上海市徐汇区宛平南路725号 |
|
Applicant address: |
725 South Wanping Road, Shanghai, People’s Republic of China. |
Study leader's address: |
725 South Wanping Road, Shanghai, People’s Republic of China. |
|
申请注册联系人邮政编码: Applicant postcode: |
200032 |
研究负责人邮政编码: Study leader's postcode: |
200032 |
|
申请人所在单位: |
上海中医药大学附属龙华医院 |
||
|
Applicant's institution: |
Longhua Hospital, Shanghai University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
上海中医药大学附属龙华医院 |
||
|
Affiliation of the Leader: |
Longhua Hospital, Shanghai University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022LCSY065 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海中医药大学附属龙华医院医学伦理委员会 |
||
|
Name of the ethic committee: |
the Ethics Committee of Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-07-28 00:00:00 | ||
|
伦理委员会联系人: |
陈晓云 |
||
|
Contact Name of the ethic committee: |
Chen xiaoyun |
||
|
伦理委员会联系地址: |
上海市徐汇区宛平南路725号 |
||
|
Contact Address of the ethic committee: |
Longhua Hospital, Shanghai University of Traditional Chinese Medicine |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
上海中医药大学附属龙华医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Longhua Hospital, Shanghai University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区宛平南路725号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
725 South Wanping Road, Shanghai, People’s Republic of China. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家中医药管理局 |
||||||||||||||||||||||
|
Source(s) of funding: |
State Administration of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究疾病: |
新冠肺炎 |
||||||||||||||||||||||
|
Target disease: |
COVID-19 |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究采用回顾性研究,评价研究中医药干预是否临床转归之间的关系,评价服用中药情况和与结局之间的关系(核酸转阴时间和住院天数,等),提升中医药疫情救治能力,为进一步的防治研究提供科学参考。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study adopts a retrospective study to evaluate the relationship between TCM Intervention and clinical outcome, and the relationship between the use of TCM and the outcome (nucleic acid negative time and hospital stay, etc.), so as to improve the ability of TCM epidemic treatment and provide scientific reference for further prevention and treatment research. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
通过回顾性的分析整理数据,将患者分为规范化暴露组与非规范化暴露组 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
The all COVID-19 cases was divided into two groups, including Chinese tradition medicine treatment with syndrome differentiation treatment(TCM class SDT group, in fact, this intervention program was provided to mild cases in cabin B and cabin C), and TCM class non SDT without Chinese tradition medicine treatment or with Chinese tradition medicine treatment without syndrome differentiation treatment( in fact, this intervention program was provided to mild cases in cabin A and cabin D). |
||||||||||||||||||||||
|
纳入标准: |
(1)年龄大于等于2岁。(2)新冠病毒无症状感染者和轻型确诊病例。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) age over 2 years old and (2) confirmed SARS-CoV-2 infection meeting the diagnostic criteria for mild type COVID-19. |
||||||||||||||||||||||
|
排除标准: |
(1)既往3个月内或正在参与其他临床试验者,(2)严重的疾病或48小时内死亡的病例。(3)严重的精神病。(4)怀孕的妇女或哺乳期的女性。(5)其他条件,如,正常参加其他的临床研究等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) patients who can not take care of themselves; (2) aggravated disease progression or death within 48 h after admission; (3) severe psychiatric disorder; (4) pregnant or lactating women; (5) other conditions, e.g., taking other herbs or participating in other clinical trials, drug withdrawal during treatment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-09-01 00:00:00至 To 2022-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-09-01 00:00:00 至 To 2022-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2024年1月开始,如果有人需要数据,请联系田雨老师,以EXCEL的格式分享数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
From January 2024, if anyone needs data, please contact Mr. Tian Yu to share the data in Excel format |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:问卷星和电子病历。 数据管理:excel. |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: questionnaire star and electronic medical record. Data management: Excel |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |